Lyrica pregabalin: Phase III data

Top-line data from the double-blind, U.S. Phase III A0081185 trial in RLS patients showed that once-daily 300 mg Lyrica met the primary endpoint of significantly improving sleep maintenance as measured by polysomnography at week 4 vs. placebo. In 2010, Pfizer discontinued development of Lyrica in RLS (see BioCentury, Oct. 4, 2010). ...